Plain-English translation of NCT05980715 on ClinicalTrials.gov ↗ · Source last updated ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study compares two different treatment approaches for patients with advanced head and neck cancer who have already had surgery and achieved a complete response to chemotherapy and immunotherapy. You would be randomly assigned to either continue treatment with a PD-1 inhibitor (the medication being tested) or receive standard radiation therapy. The trial wants to know whether the medication works as well as radiation at preventing cancer from coming back.
Standard treatment after surgery for this type of cancer involves radiation therapy, which can cause serious long-term side effects like second cancers and bone damage. This trial exists to see if continuing immunotherapy could be just as effective while avoiding the harmful effects of radiation.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: either take the PD-1 inhibitor medication as ongoing treatment, or receive standard radiation therapy (with or without chemotherapy). The study will follow you for at least 5 years, tracking whether your cancer stays away, any side effects you experience, and your overall health. You will have regular clinic visits, blood tests, and imaging scans to monitor your progress.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China